December 26, 2007
Genta Receives Nasdaq Non-Compliance Notice
December 21, 2007
FDA To Extend Review Of Data Quality Submission For Genasense® In Melanoma
December 10, 2007
Genasense plus Chemotherapy is Associated with Prolonged Survival in Patients with Relapsed/Refractory CLL who Achieve Complete Remission
December 4, 2007
Genta Clinical Programs Featured at American Society of Hematology Meeting
November 26, 2007
Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
November 16, 2007
Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
November 15, 2007
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
November 8, 2007
Genasense® Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
November 7, 2007
Genta Incorporated Announces Third Quarter 2007 Financial Results
October 31, 2007
Genta Incorporated to Present At The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
October 30, 2007
Genta Incorporated to Host Conference Call to Discuss Third Quarter Highlights and Financial Results
October 26, 2007
Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
October 25, 2007
Genta Completes Appeal of FDA Decision for Genasense® in CLL
October 24, 2007
Genasense® Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
October 23, 2007
Genasense® Can be Administered by Brief High-Dose IV Infusion
October 18, 2007
Genta Announces Presentation of New Clinical and Preclinical Data on Genasense® at AACR-NCI-EORTC “Targets” Conference
October 17, 2007
Authorization for AGENDA Phase 3 Trial of Genasense® in Advanced Melanoma Granted by French Regulatory Agency
October 4, 2007
Genta To Present At BIO Investor Forum 2007 Conference
September 17, 2007
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
September 13, 2007
Genasense® Clinical Data in Patients with Advanced Melanoma and Chronic Lymphocytic Leukemia to be Presented at ECCO Meeting in Barcelona
September 5, 2007
Genasense® Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
August 28, 2007
Genta Incorporated To Present At The Roth Capital Partners New York Conference
August 21, 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense® for Patients with Advanced Melanoma
August 13, 2007
Genta Announces Launch of Genasense® Named-Patient/Compassionate Use Program
August 7, 2007
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
August 2, 2007
Genta Incorporated to Host Conference Call to Discuss Second Quarter Highlights and Financial Results
August 1, 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
July 30, 2007
Genta Receives Notice of Compliance for Continued Listing on NASDAQ Global Market
July 19, 2007
EMEA Indicates that Genasense® Approval in Melanoma Will Require Confirmatory Clinical Trial
July 12, 2007
NASDAQ Grants Extension for Genta to Comply with Listing Requirements
July 3, 2007
Genta Announces Webcast of 2007 Annual Shareholders Meeting
June 18, 2007
Genta to Request Review of FDA Action for Genasense® NDA in Chronic Lymphocytic Leukemia
June 6, 2007
Genta Announces Results of Phase 1 Study using Genasense Administered by Intermittent Subcutaneous Injection
June 4, 2007
Phase 2 Clinical Results of Ganite® Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
May 25, 2007
Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
May 8, 2007
Genta Incorporated Announces First Quarter 2007 Financial Results and Clinical, Regulatory, Financial and Commercial Strategy
May 2, 2007
Genta to Appeal Staff Notice from NASDAQ Regarding Listing on NASDAQ Global Market
April 30, 2007
Genta Incorporated to Host Conference Call to Discuss First Quarter Highlights and Financial Results
April 27, 2007
CHMP Adopts Negative Opinion on Genasense® Application in Melanoma
April 18, 2007
Genta Announces New Phase 3 Trial of Genasense® in Patients with Advanced Melanoma
April 4, 2007
Genta Appeals FDA Decision on Genasense in CLL
March 23, 2007
Genta Announces Expectation of a Negative Opinion from the CHMP on Genasense Application for Advanced Melanoma
March 15, 2007
Genta Announces Closing of Common Stock Offering
March 14, 2007
Genta Announces Common Stock Offering of Approximately $11 Million
March 7, 2007
Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite® and Genasense®
February 23, 2007
Phase 2 Results of Genasense® Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference
February 14, 2007
Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated with Genasense® Plus Chemotherapy
February 13, 2007
Genta Incorporated Announces Fourth Quarter and Year End 2006 Financial Results and Corporate Highlights
February 7, 2007
Genta Incorporated to Host Conference Call to Discuss Fourth Quarter Highlights and 2006 Financial Results
February 6, 2007
Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense® in Chronic Lymphocytic Leukemia
February 2, 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense® Marketing Authorization Application in Melanoma
